MX2010000937A - Tratamiento del trastorno por estrés postraumático. - Google Patents

Tratamiento del trastorno por estrés postraumático.

Info

Publication number
MX2010000937A
MX2010000937A MX2010000937A MX2010000937A MX2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A MX 2010000937 A MX2010000937 A MX 2010000937A
Authority
MX
Mexico
Prior art keywords
post
stress disorder
traumatic stress
patient
compound
Prior art date
Application number
MX2010000937A
Other languages
English (en)
Spanish (es)
Inventor
Tom Woiwode
Mark Moran
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of MX2010000937A publication Critical patent/MX2010000937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2010000937A 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático. MX2010000937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93503607P 2007-07-23 2007-07-23
PCT/US2008/070948 WO2009015248A1 (en) 2007-07-23 2008-07-23 Treatment of post-traumatic stress disorder

Publications (1)

Publication Number Publication Date
MX2010000937A true MX2010000937A (es) 2010-06-25

Family

ID=40281815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010000937A MX2010000937A (es) 2007-07-23 2008-07-23 Tratamiento del trastorno por estrés postraumático.

Country Status (12)

Country Link
US (1) US20090054403A1 (OSRAM)
EP (1) EP2182952A4 (OSRAM)
JP (1) JP2010534676A (OSRAM)
CN (1) CN101951912A (OSRAM)
AU (1) AU2008279091A1 (OSRAM)
CA (1) CA2707858A1 (OSRAM)
CO (1) CO6260078A2 (OSRAM)
MX (1) MX2010000937A (OSRAM)
NZ (1) NZ583193A (OSRAM)
RU (1) RU2458691C2 (OSRAM)
SG (1) SG183069A1 (OSRAM)
WO (1) WO2009015248A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182803A4 (en) * 2007-07-23 2010-09-01 Synosia Therapeutics (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER
SG10201705968RA (en) * 2007-08-06 2017-08-30 Biotie Therapies Inc Methods for treating dependence
AU2016208412A1 (en) * 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
NZ747040A (en) 2013-03-15 2020-02-28 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US11885816B2 (en) * 2013-11-26 2024-01-30 University Of North Texas Health Science Center At Forth Worth Personalized medicine approach for treating cognitive loss
SG11201701995PA (en) 2014-09-18 2017-04-27 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
RU2614697C1 (ru) * 2016-04-12 2017-03-28 Общество с ограниченной ответственностью "Нормофарм" Нейропротекторное средство
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
CN110996987A (zh) * 2017-05-30 2020-04-10 保罗·G·爱默生 用于调控应激障碍中激素级联的组合物和方法
US11284934B2 (en) * 2017-07-05 2022-03-29 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating sleep disorders in patients via renal neuromodulation
JP7167155B2 (ja) 2017-12-04 2022-11-08 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ ドーパミン－β－ヒドロキシラーゼ阻害剤
AU2018383098B2 (en) 2017-12-11 2024-12-12 Tonix Pharma Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN109966281B (zh) * 2019-04-11 2021-04-27 北京大学 PAO作为Pi4KIIα抑制剂在制备治疗创伤后应激障碍药物中的应用
EP4005566B1 (en) * 2019-07-25 2024-10-30 Tokyo University of Science Foundation Disulfiram and related compounds for treating, preventing or improving anxiety disorders or symptoms, and depressive disorders or symptoms
AU2023400662A1 (en) * 2022-11-30 2025-06-19 Blinklab Ltd Psychopharmacological system and method using eyelid tracking

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
WO2003022283A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
MX2008000248A (es) * 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y un antidepresivo y metodos de tratamiento contra la menopausia y trastornos del estado de animo, la ansiedad y trastornos cognitivos.
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
US20090054414A1 (en) * 2007-07-23 2009-02-26 Synosia Therapeutics Rufinamide for the Treatment of Post-Traumatic Stress Disorder

Also Published As

Publication number Publication date
NZ583193A (en) 2012-05-25
US20090054403A1 (en) 2009-02-26
WO2009015248A1 (en) 2009-01-29
CA2707858A1 (en) 2009-01-29
SG183069A1 (en) 2012-08-30
CN101951912A (zh) 2011-01-19
EP2182952A4 (en) 2010-09-08
CO6260078A2 (es) 2011-03-22
JP2010534676A (ja) 2010-11-11
RU2010106014A (ru) 2011-08-27
RU2458691C2 (ru) 2012-08-20
EP2182952A1 (en) 2010-05-12
AU2008279091A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
MX2009012307A (es) Tratamiento de sinucleinopatias.
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA201001771A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
WO2013033657A3 (en) CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
MX391921B (es) Nepicastat para usarse en el tratamiento de dependencia
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
TN2011000413A1 (en) Sglt-2inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus impaired glucose tolerance or hyperglycemia
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
NZ603717A (en) Suture line administration technique using botulinum toxins
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX2009008135A (es) Uso de histidinato de cromo para tratamiento de alteraciones cardiometabolicas.
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
MX2010000938A (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
NZ611614A (en) Compositions and methods for treating amyloid plaque associated symptoms
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
WO2006113900A3 (en) Methods and devices for relieving stress
IN2012DN00549A (OSRAM)
EP2566502A4 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIOTIE THERAPIES, INC.*

FA Abandonment or withdrawal